The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Open accessAbstract
Differential regulation of telomerase activity in normal and tumor cells provides a rationale for the design of new classes of telomerase inhibitors. The telomerase enzyme complex presents multiple potential sites for the development of inhibitors. GRN163L, a telomerase enzyme antagonist, is a lipid-modified 13-mer oligonucleotide N3′ → P5′-thio-phosphoramidate, complementary to the template region of telomerase RNA (hTR). We evaluated both the in vitro and in vivo effects of GRN163L using A549-luciferase (A549-Luc) human lung cancer cells expressing a luciferase reporter. GRN163L (1 μmol/L) effectively inhibits telomerase activity of A549-Luc cells, resulting in progressive telomere shortening. GRN163L treatment also reduces colony formation in soft agar assays. Surprisingly, after only 1 week of treatment with GRN163L, A549-Luc cells were unable to form robust colonies in the clonal efficiency assay, whereas the mismatch control compound had no effect. Finally, we show that in vivo treatment with GRN163L is effective in preventing lung metastases in xenograft animal models. These in vitro and in vivo data support the development of GRN163L as a therapeutic for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GRN163L is a modified oligonucleotide complementary to hTERC and a potent and specific telomerase antagonist66.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [66]
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 1×
“Telomerase is active in 85% to 90% of all human tumors but not in normal somatic cells with the exception of germ line and select progenitor cell populations (10, 11).”
BackgroundSelf-citationA survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 1×
“Telomerase is active in 85% to 90% of all human tumors but not in normal somatic cells with the exception of germ line and select progenitor cell populations (10, 11).”
BackgroundSelf-citationCounter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096
Telomere end-replication problem and cell aging
Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., & Harley, C. B. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90096-3 · Cited by 1,069
Inhibition of telomerase limits the growth of human cancer cells
Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., & Weinberg, R. A. (1999) · Nature Medicine · doi:10.1038/13495 · Cited by 1,030
Shay, J. W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.677 · Cited by 509
Self-citationHallmarks of senescence in carcinogenesis and cancer therapy
Shay, J. W., & Roninson, I. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207518 · Cited by 502 · cited 1×
“In humans, they are initially composed of f15 to 20 kbp of hexameric TTAGGG double-stranded DNA repeats followed by a single-strand overhang of the 3V-G-rich strand that is inserted back into the double-strand DNA in a lariat-like structure called the t-loop (1).”
BackgroundSelf-citationA highly selective telomerase inhibitor limiting human cancer cell proliferation
Damm, K., Hemmann, U., Garin‐Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6958 · Cited by 422
Wright, W. E., & Shay, J. W. (2000) · Nature Medicine · doi:10.1038/78592 · Cited by 398
Self-citationChemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
Cited by
Collins, T. J. (2007) · BioTechniques · doi:10.2144/000112517 · Cited by 2,124
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
“…and inhibits tumor angiogenesis Maira et al., 2008 GRN163L (modified oligo) hTERT OA Mimics telomere sequence and inhibits the hTERT active site Dikmen et al., 2005; Harley, 2008 GRNVAC1 (cell therapy) hTERT OA Autologous dendritic cells transduced to express an hTERT-LAMP fusion protein to…”
Aubert, G., & Lansdorp, P. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00026.2007 · Cited by 1,188
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Metadata
- Authors
- Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W.
- Affiliations
- 1University of Hacettepe, Faculty of Medicine, Department of Biochemistry, Ankara, Turkey;
- The University of Texas Southwestern Medical Center (US)
- Geron (United States) (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Venue
- Cancer Research
- Published
- 2005-09-01
- Volume
- 65
- Issue
- 17
- Pages
- 7866-7873
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2125343208
- Cited by
- 271
- References
- 47
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 10 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 13 · 2019: 8 · 2018: 14 · 2017: 7 · 2016: 12 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 7
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- Funders
- National Cancer Institute (P50CA75907, CA86354, P20CA086354)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- GRN163L, telomerase inhibitors, lung cancer, telomerase RNA template, phosphoramidate prodrug, telomere shortening, A549 cells, colony formation, lung metastasis, xenograft models, cancer therapy
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Liposomes, Luciferases, Lung Neoplasms, Mice, Nude, Oligonucleotides, Sulfur Radioisotopes, Tissue Distribution, Neoplastic Stem Cells, Telomerase, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-1215
- The paper
- Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005). In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-1215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.